Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Erlotinib
Drug: Second-Line Chemotherapy

First Posted Date: 2011-04-05

Last Posted Date: 2016-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 643

Registration Number: NCT01328951

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Phase 2

Completed

Conditions: Myocardial Infarction

Interventions: Procedure: Percutaneous Coronary Intervention (PCI)
Drug: RO4905417
Drug: placebo

First Posted Date: 2011-04-01

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 532

Registration Number: NCT01327183

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]

First Posted Date: 2011-03-31

Last Posted Date: 2017-08-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT01326962

Locations: 🇸🇦
Heraa General Hospital; Rheumatology, Makkah, Saudi Arabia
🇸🇦
King Abdulaziz University Hospital, Jeddah, Saudi Arabia
🇸🇦
King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia

and more 1 locations

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFIRI
Drug: RO5083945
Drug: cetuximab

First Posted Date: 2011-03-30

Last Posted Date: 2022-11-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 169

Registration Number: NCT01326000

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Phase 3

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: dalcetrapib
Drug: placebo

First Posted Date: 2011-03-25

Last Posted Date: 2019-07-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 300

Registration Number: NCT01323153

An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer

Completed

Conditions: Colorectal Cancer

First Posted Date: 2011-03-22

Last Posted Date: 2016-09-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 609

Registration Number: NCT01319877

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis

Completed

Conditions: Kidney Disease, Chronic

First Posted Date: 2011-03-18

Last Posted Date: 2017-07-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 340

Registration Number: NCT01318512

Locations: 🇨🇿
Nemocnice Novy Jicin; Dialyzacni Stredisko, Novy Jicin, Czechia

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2011-03-07

Last Posted Date: 2018-09-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 208

Registration Number: NCT01310036

Locations: 🇨🇳
Changhua Christian Hospital; Internal Medicine, Changhua, Taiwan
🇨🇳
Veterans General Hospital; Internal Medicine, Kaohsiung, Taiwan
🇨🇳
Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan

and more 19 locations

Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine

Completed

Conditions: Anemia

First Posted Date: 2011-03-07

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1083

Registration Number: NCT01309269

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2011-03-07

Last Posted Date: 2016-08-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT01309282

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy